High Frequency Ultrasound to develop a platform for Intradermal injections in children
•
1 like•245 views
Novosanis is developing the VAX-ID platform suited for accurate drug delivery of e.g. vaccines in the dermal layer of the skin. To address the market needs with regard to application, injection site and age range, different variants are being developed. In particular, for children aged 8 weeks to 18 years, a variant is in development allowing for accurate and painless, but also user-friendly intradermal administration. In this regard; the current study aimed to assess skin thickness of children as key driver in the device development an (rapid) prototyping.
